L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia.

@article{Warrington1989LhistidinolIT,
  title={L-histidinol improves the selectivity and efficacy of alkylating agents and daunomycin in mice with P388 leukaemia.},
  author={Robert C. Warrington and Wei D. Fang},
  journal={British Journal of Cancer},
  year={1989},
  volume={60},
  pages={652 - 656}
}
DBA/2J mice bearing a clonal isolate of the transplantable murine lymphocytic leukaemia line P388 were used to examine the effects of L-histidinol on the antitumour activity of three alkalyating agents (bis-chloroethylnitrosourea (BCNU), cis-diamminedichloroplatinum (II) (cisDDP) and cyclophosphamide) and the antitumour antibiotic daunomycin. [] Key Result Single, combined treatments with L-histidinol and either BCNU or cisDDP, at doses of the alkylating agents which were ineffective when used alone, were…

Figures and Tables from this paper

L-histidinol: preclinical therapeutic studies in combination with antitumor agents and pharmacokinetic studies in mice.
Therapeutic studies were conducted with L-histidinol, in combination with cyclophosphamide, bischloroethylnitrosourea, 5-fluorouracil, phenylalanine mustard, or cis-platinum(II)diammine dichloride,
Preclinical antitumor activity of ethyldeshydroxysparsomycin in combination with cisplatin
TLDR
It is suggested that EDSM has significant synergistic capabilities in both animal tumor models, but strong therapeutic enhancement of cisplatin efficacy is only seen when the tumor is sensitive to CDDP.
L-Histidinol Attenuates Fanconi Syndrome Induced by Ifosfamide in Rats
  • O. Badary
  • Biology, Medicine
    Nephron Experimental Nephrology
  • 1999
TLDR
Oral supplementation of LHL can partially protect against IFO-induced Fanconi syndrome (FS) induced by IFO in rats, with beneficial effects on renal dysfunction and nonprotein sufhydry depletion and lipid peroxide accumulation.
Antibody directed enzyme prodrug therapy (ADEPT). A review of some theoretical, experimental and clinical aspects.
TLDR
A pilot scale clinical trial indicated the feasibility of antibody directed enzyme prodrug therapy (ADEPT), and the difference between prodrug and active drug creates the opportunity to degrade active drug selectively in blood and thus protect normal tissues.
R-2HMP: an Orally Active Agent Combining Independent Antiapoptotic and MAO-B-Inhibitory Activities
TLDR
The present review will describe the development and known activity of the lead compound R-N-(2heptyl)-N-methylpropargylamine hydrochloride (R-2HMP) and at least one of the metabolites of this lead compound appears to be responsible for the antiapoptotic effect while being essentially devoid of MAO-B-inhibitory activity.
Strategies of Protection of Normal Cells During Chemo- and Radio-Therapy Based on Modulation of Cell Cycle and Apoptotic Pathways
TLDR
The ultimate goal of cancer therapy is to selectively kill cancer cells, while sparing normal cells, and BCR-ABL, a product of a chromosomal translocation, is the most validated target in oncology.
PROPARGYLAMINE FOR ENHANCING CANCER THERAPY
TLDR
L-Histidinol in experimental che motherapy: improving the Selectivity and efficacy of anti cancer drugs, eliminating metastatic disease and revering the multi-drug resistant phenotype.
Inhibition of protein N-myristoylation: a therapeutic protocol in developing anticancer agents.
TLDR
The current review focuses on developments of various chemical NMT inhibitors with potential roles as anticancer agents.
...
1
2
...

References

SHOWING 1-10 OF 17 REFERENCES
Histidinol-mediated improvement in the specificity of 1-beta-D-arabinofuranosylcytosine and 5-fluorouracil in L 1210 leukemia-bearing mice.
TLDR
It is reported here that histidinol confers substantial protection upon the bone marrow cells of DBA/2J mice from the drugs 1-beta-D-arabinofuranosylcytosine and 5-fluorouracil without diminishing the toxicities of these agents for in situ leukemia cells.
Effects of L-histidinol on the susceptibility of P815 mastocytoma cells to selected anticancer drugs in vitro and in DBA/2J mice.
TLDR
Quantitative cell survival assays of murine bone marrow cells and of clonogenic tumor cells obtained from treated animals demonstrated that L-histidinol eliminated the bone marrow toxicity otherwise attending the use of the drugs ara-C and FUra.
Failure of L-histidinol to improve the therapeutic efficiency of 5-fluorouracil against murine breast tumors.
TLDR
The results of these studies indicate that the administration of L-histidinol can protect the CD8F1 mouse from FUra-associated leukopenia, body weight loss, and ultimately, from mortality.
Specificity, schedule, and proliferation dependence of infused L-histidinol after 5-fluorouracil in mice.
TLDR
It is demonstrated that the FUra/L-histidinol combination indeed protects only normal cells but that the postulated proliferation dependence is absent, indicating an alternate biological mechanism.
A novel approach for improving the efficacy of experimental cancer chemotherapy using combinations of anticancer drugs and L-histidinol.
TLDR
Results demonstrate that the L-histidinol/anticancer drug combination approach to chemotherapy is effective with a variety of clinically-relevant antineoplastic agents.
Histidinol-mediated enhancement of the specificity of two anticancer drugs in mice bearing leukemic bone marrow disease.
TLDR
L-histidinol mediates a substantial increase in the specificities of ara-C and FUra in mice bearing an established bone marrow leukemic condition and increased significantly the toxicities of these agents for the intrafemoral tumor cells.
Reversal of the multidrug-resistant phenotype of Chinese hamster ovary cells by L-histidinol.
The amino acid analogue L-histidinol reverses the multidrug-resistance (MDR) attribute of the colchicine-resistant (CHR) variant CHRC5, a Chinese hamster ovary cell line that overexpresses a plasma
Effect of L
  • 1988
Effect of Lhistidinol on the metabolism of 5-fluorouracil in the BALB/ c x DBA/8 Fl murine model system
  • Cancer Res
  • 1988
Effect of Lhistidinol on the metabolism of 5-fluorouracil in the BALB/ c x DBA/8 Fl murine model system
  • Cancer Res
  • 1988
...
1
2
...